Amgen Forecast, price target & analysts
Amgen Target price 2025 - Analyst rating & recommendation
Amgen Classifications & Recommendation:
Amgen Price Target
| Target Price | $321.30 |
| Price | $336.00 |
| Deviation | 4.38% |
| Number of Estimates | 31 |
| 31 Analysts have issued a price target Amgen 2026 . The average Amgen target price is $321.30. This is 4.38% lower than the current stock price. The highest price target is $425.25 26.56% , the lowest is $181.80 45.89% . | |
| A rating was issued by 40 analysts: 21 Analysts recommend Amgen to buy, 16 to hold and 3 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Amgen stock has an average upside potential 2026 of 4.38% . Most analysts recommend the Amgen stock at Purchase. |
Sales and Margin forecast 2025, 2026 to 2032
34 Analysts have issued a sales forecast Amgen 2025 . The average Amgen sales estimate is $36.4b . This is 1.12% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $38.0b 5.77% , the lowest is $34.4b 4.50% .
This results in the following potential growth metrics:
Revenue Estimates
| 2024 | $33.4b | 18.57% |
|---|---|---|
| 2025 | $36.4b | 8.82% |
| 2026 | $37.0b | 1.84% |
| 2027 | $38.1b | 2.73% |
| 2028 | $38.4b | 0.96% |
| 2029 | $39.7b | 3.24% |
| 2030 | $41.4b | 4.44% |
| 2031 | $42.2b | 1.95% |
| 2032 | $43.4b | 2.69% |
34 Amgen Analysts have issued a net profit forecast 2025. The average Amgen net profit estimate is $11.5b . This is 64.74% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $12.1b 73.14% , the lowest is $10.8b 54.67% .
This results in the following potential growth metrics and future Net Margins:
Net Profit Estimates
| 2024 | $4.1b | 39.11% |
|---|---|---|
| 2025 | $11.5b | 182.15% |
| 2026 | $11.8b | 2.57% |
| 2027 | $12.3b | 3.91% |
| 2028 | $12.5b | 1.94% |
| 2029 | $13.1b | 4.11% |
| 2030 | $13.9b | 6.69% |
| 2031 | $14.3b | 2.57% |
| 2032 | $15.3b | 6.88% |
Net Margin
| 2024 | 12.24% | 48.64% |
|---|---|---|
| 2025 | 31.73% | 159.30% |
| 2026 | 31.95% | 0.69% |
| 2027 | 32.32% | 1.16% |
| 2028 | 32.63% | 0.96% |
| 2029 | 32.91% | 0.86% |
| 2030 | 33.62% | 2.16% |
| 2031 | 33.82% | 0.59% |
| 2032 | 35.20% | 4.08% |
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
34 Analysts have issued a Amgen forecast for earnings per share. The average Amgen EPS is $21.45 . This is 65.77% higher than earnings per share in the financial year 2024. The highest EPS forecast is $22.54 74.19% , the lowest is $20.14 55.64% .
This results in the following potential growth metrics and future valuations:
Earnings Per Share
| 2024 | $7.56 | 39.47% |
|---|---|---|
| 2025 | $21.45 | 183.73% |
| 2026 | $22.00 | 2.56% |
| 2027 | $22.86 | 3.91% |
| 2028 | $23.31 | 1.97% |
| 2029 | $24.26 | 4.08% |
| 2030 | $25.89 | 6.72% |
| 2031 | $26.55 | 2.55% |
| 2032 | $28.38 | 6.89% |
P/E ratio
| Current | 25.97 | 37.58% |
|---|---|---|
| 2025 | 15.66 | 39.69% |
| 2026 | 15.27 | 2.49% |
| 2027 | 14.70 | 3.73% |
| 2028 | 14.42 | 1.90% |
| 2029 | 13.85 | 3.95% |
| 2030 | 12.98 | 6.28% |
| 2031 | 12.66 | 2.47% |
| 2032 | 11.84 | 6.48% |
Based on analysts' sales estimates for 2025, the Amgen stock is valued at an EV/Sales of 6.22 and an P/S ratio of 4.97 .
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 6.28 | 9.64% |
|---|---|---|
| 2025 | 6.22 | 1.03% |
| 2026 | 6.10 | 1.81% |
| 2027 | 5.94 | 2.66% |
| 2028 | 5.88 | 0.95% |
| 2029 | 5.70 | 3.14% |
| 2030 | 5.46 | 4.25% |
| 2031 | 5.35 | 1.91% |
| 2032 | 5.21 | 2.62% |
P/S ratio
| Current | 5.03 | 6.41% |
|---|---|---|
| 2025 | 4.97 | 1.11% |
| 2026 | 4.88 | 1.81% |
| 2027 | 4.75 | 2.66% |
| 2028 | 4.71 | 0.95% |
| 2029 | 4.56 | 3.14% |
| 2030 | 4.37 | 4.26% |
| 2031 | 4.28 | 1.91% |
| 2032 | 4.17 | 2.62% |
Current Amgen Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Cantor Fitzgerald |
Neutral
➜
Neutral
|
Unchanged | Nov 06 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Nov 05 2025 |
| Wells Fargo |
Overweight
➜
Overweight
|
Unchanged | Nov 05 2025 |
| B of A Securities |
Underperform
➜
Underperform
|
Unchanged | Sep 26 2025 |
| Piper Sandler |
Overweight
➜
Overweight
|
Unchanged | Aug 25 2025 |
| Citigroup |
Neutral
➜
Neutral
|
Unchanged | Aug 06 2025 |
| Morgan Stanley |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Aug 06 2025 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
Cantor Fitzgerald:
Neutral
➜
Neutral
|
Nov 06 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Nov 05 2025 |
|
Unchanged
Wells Fargo:
Overweight
➜
Overweight
|
Nov 05 2025 |
|
Unchanged
B of A Securities:
Underperform
➜
Underperform
|
Sep 26 2025 |
|
Unchanged
Piper Sandler:
Overweight
➜
Overweight
|
Aug 25 2025 |
|
Unchanged
Citigroup:
Neutral
➜
Neutral
|
Aug 06 2025 |
|
Unchanged
Morgan Stanley:
Equal-Weight
➜
Equal-Weight
|
Aug 06 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
